New Types of Antibiotics Are Key to Fighting Drug-Resistant Bacteria

What are ‘novel’ antibiotics and why do we need them?

Antibiotics research

Bacterial resistance to one antibiotic often leads to resistance to similar types of antibiotics, so novel classes of antibiotics—drugs that are significantly different from existing antibiotics in core molecular structure or mode of attack —are critically needed to stay ahead of resistance.

© The Pew Charitable Trusts

Note: This analysis was updated in December 2017 to reflect new data on the number of antibiotics in development belonging to existing classes.

To ensure that we have effective medicines to treat the drug-resistant bacterial infections of today as well as those that emerge in the future, antibiotic innovation must include both the discovery of new types of antibiotics and improvements to existing drugs.

New types of antibiotics are essential

Nearly all of the antibiotics currently available are based on discoveries made over 30 years ago. And of the antibiotics in clinical development for the U.S. market, 75 percent belong to existing types—or “classes”—of drugs against which bacterial resistance has already been observed or could easily develop.

A drug class is a group of antibiotics that share a common core molecular structure, commonly referred to as a scaffold.

Bacterial resistance to one antibiotic often leads to resistance to similar types of antibiotics, so novel classes of antibiotics—drugs that are significantly different from existing antibiotics in core molecular structure or mode of attack are critically needed to stay ahead of resistance.

The challenge is that novel classes of antibiotics are difficult for scientists to find due to key scientific barriers. For example, it is particularly challenging to find antibiotics that work against some of the toughest bugs out there—Gram-negative bacteria, which have a built-in gantlet of defenses that is hard to overcome.

Giving old antibiotics new capabilities can help overcome resistance

Another important source of innovation that can help address resistance in the near term is improving existing drug types to preserve their effectiveness. For example, modifications to antibiotics could enhance their ability to get through to and destroy drug-resistant bacteria. Another approach is to develop therapies that combine the properties of two or more drugs into a joint molecular structure or to augment an antibiotic with an extra molecule that helps stifle the resistance capabilities of bacteria, enabling the drug to do its job effectively. Scientists have had some initial success in this realm, as demonstrated by the approval of Avycaz, a combination of an existing antibiotic (ceftazidime) and a molecule that overcomes resistance (avibactam).

Building a diverse pipeline of new and improved treatments

Patients need new treatments, particularly for hard-to-treat infections such as those caused by Gram-negative ESKAPE, as well as Clostridium difficile, carbapenem-resistant Enterobacteriaceae, and drug-resistant gonorrhea.

Finding new classes of antibiotics will require ambitious efforts to spur early stage antibiotic discovery, such as the targeted, multidisciplinary research initiative that is outlined in The Pew Charitable Trusts’ 2016 report A Scientific Roadmap for Antibiotic Discovery.

Moving forward, efforts like the Combating Antibiotic-Resistant Bacteria Accelerator (CARB-X) program, a global public-private partnership to stimulate the development of promising new therapies, will also be important. Among its priority focus areas, CARB-X aims to support therapeutics to treat Gram-negative bacteria and novel, high-risk products that may not otherwise receive the funding needed for early stage development.

Antibiotic innovation—finding and designing new types of antibiotics and improving existing drugs—is essential to ensure that we have effective antibiotics available to treat serious bacterial infections over the decades to come.

Carolyn Shore works on the antibiotic resistance project for The Pew Charitable Trusts.

Spotlight on Mental Health

Issue Brief

Tracking the Global Pipeline of Antibiotics in Development

Quick View
Issue Brief

Drug-resistant bacteria, or superbugs, present a serious and worsening threat to human health. According to a report from the Centers for Disease Control and Prevention, 2 million Americans acquire serious infections caused by antibiotic-resistant bacteria each year, and 23,000 of them die as a result.

Composite image of modern city network communication concept

Learn the Basics of Broadband from Our Limited Series

Sign up for our four-week email course on Broadband Basics

Quick View

How does broadband internet reach our homes, phones, and tablets? What kind of infrastructure connects us all together? What are the major barriers to broadband access for American communities?

Pills illustration
Pills illustration

What Is Antibiotic Resistance—and How Can We Fight It?

Sign up for our four-week email series The Race Against Resistance.

Quick View

Antibiotic-resistant bacteria, also known as “superbugs,” are a major threat to modern medicine. But how does resistance work, and what can we do to slow the spread? Read personal stories, expert accounts, and more for the answers to those questions in our four-week email series: Slowing Superbugs.

Explore Pew’s new and improved
Fiscal 50 interactive

Your state's stats are more accessible than ever with our new and improved Fiscal 50 interactive:

  • Maps, trends, and customizable charts
  • 50-state rankings
  • Analysis of what it all means
  • Shareable graphics and downloadable data
  • Proven fiscal policy strategies


Welcome to the new Fiscal 50

Key changes include:

  • State pages that help you keep track of trends in your home state and provide national and regional context.
  • Interactive indicator pages with highly customizable and shareable data visualizations.
  • A Budget Threads feature that offers Pew’s read on the latest state fiscal news.

Learn more about the new and improved Fiscal 50.